At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Trading 04-22 15:34:15 EDT
528.18
+0.49
+0.09%
High536.02Low523.24Vol148.22K
Open531.69D1 Closing527.69Amplitude2.42%
Mkt Cap12.12BTradable Cap5.81BTotal Shares22.94M
T/O78.51MT/O Rate1.35%Tradable Shares11.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
GlobeNewswire  ·  04-22 20:00
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
Madrigal grants 5,758 inducement RSUs to 12 new employees under 2025 plan
Reuters  ·  04-22 04:14
Madrigal grants 5,758 inducement RSUs to 12 new employees under 2025 plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  04-22 04:05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge?
Simply Wall St.  ·  04-10
Is It Too Late To Consider Madrigal Pharmaceuticals (MDGL) After Recent Share Price Surge?
Madrigal grants 8,079 inducement RSUs to 20 new employees under 2025 plan
Reuters  ·  04-08
Madrigal grants 8,079 inducement RSUs to 20 new employees under 2025 plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  04-08
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Strength And Updated Fair Value Estimate
Simply Wall St.  ·  03-28
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Strength And Updated Fair Value Estimate
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
TIPRANKS  ·  03-27
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
Analysts’ Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)
TIPRANKS  ·  03-23
Analysts’ Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)
Madrigal Pharmaceuticals grants 1,739 inducement RSUs under 2025 plan
Reuters  ·  03-20
Madrigal Pharmaceuticals grants 1,739 inducement RSUs under 2025 plan
Madrigal Pharmaceuticals EVP and CFO Mardi Dier Disposes of Common Shares
Reuters  ·  03-07
Madrigal Pharmaceuticals EVP and CFO Mardi Dier Disposes of Common Shares
Madrigal Pharmaceuticals grants inducement equity awards to 20 new employees
Reuters  ·  03-06
Madrigal Pharmaceuticals grants inducement equity awards to 20 new employees
Madrigal Pharmaceuticals to Participate in TD Cowen 46th Annual Health Care Conference
Reuters  ·  02-24
Madrigal Pharmaceuticals to Participate in TD Cowen 46th Annual Health Care Conference
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales
Simply Wall St.  ·  02-24
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales
Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)
TIPRANKS  ·  02-22
Barclays Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities
Dow Jones  ·  02-20
Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities
Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
TIPRANKS  ·  02-20
Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating
TIPRANKS  ·  02-20
Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating
Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss
Stock Track  ·  02-19
Stock Track | Madrigal Pharmaceuticals Plummets 8.75% in Pre-Market on Wider-Than-Expected Q4 Net Loss
BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss
Reuters  ·  02-19
BUZZ-Madrigal Pharmaceuticals down after wider-than-expected Q4 net loss

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--